Sign in
Stories
Advancements in Clinical Trials
Share
Breakthrough Therapy Shows Positive Resu...
FDA Clearance for NOX-A12 Phase 2 Trial
FDA Clears NOX-A12 for Glioblastoma
Overview
API
CNS Pharmaceuticals and Be Biopharma make significant advancements in their respective clinical trials. CNS Pharmaceuticals presents updated safety data for Berubicin, a potentially pivotal treatment for Glioblastoma Multiforme (GBM), while Be Biopharma is set to present at the 35th Annual Piper Sandler Healthcare Conference. CNS Pharmaceuticals has achieved enrollment of 229 patients in its ongoing study of Berubicin, with Fast Track Designation and Orphan Drug Designation from the FDA.
Ask a question
How might the Fast Track Designation and Orphan Drug Designation impact the development and regulatory approval of Berubicin?
How might the rapid pace of enrollment in CNS Pharmaceuticals' study of Berubicin affect the treatment landscape for Glioblastoma Multiforme (GBM)?
What are the potential implications of Be Biopharma's presentation at the 35th Annual Piper Sandler Healthcare Conference on the future of engineered B Cell Medicines?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jul 2023
Aug 2023
Sep 2023
Oct 2023
Nov 2023
Coverage